Nisa Investment Advisors, LLC Cyma Bay Therapeutics, Inc. Transaction History

Nisa Investment Advisors, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 25, 2024	SELL	$12.63 - $24.47 $11,114 - $21,533	-880 Reduced 42.09%	1,211 $28,000
Q3 2023 Nov 02, 2023	BUY	$10.86 - $17.62 $9,556 - $15,505	880 Added 72.67%	2,091 $31,000
Q2 2023 Aug 11, 2023	BUY	$7.47 - $10.95 $455 - $667	61 Added 5.3%	1,211 $13,000
Q2 2022 Aug 03, 2022	SELL	$1.72 - $3.39 $7,430 - $14,644	-4,320 Reduced 78.98%	1,150 $3,000
Q1 2022 Apr 29, 2022	SELL	$2.77 - $3.64 $13,850 - $18,200	-5,000 Reduced 47.76%	5,470 $17,000
Q4 2021 Feb 03, 2022	BUY	$3.23 - $4.6 $30,103 - $42,872	9,320 Added 810.43%	10,470 $31,000
Q1 2021 Apr 26, 2021	SELL	$4.23 - $6.55 $6,345 - $9,825	-1,500 Reduced 56.6%	1,150 $5,000
Q4 2020 Jan 25, 2021	BUY	$5.73 - $9.03 $7,162 - $11,287	1,250 Added 89.29%	2,650 $15,000
Q2 2020 Jul 27, 2020	BUY	$1.41 - $4.25 $1,974 - $5,950	1,400 New	1,400 $5,000
Q1 2020 Apr 17, 2020	SELL	$1.25 - $2.02 $2,350 - $3,797	-1,880 Closed	0 $0
Q4 2019 Jan 17, 2020	BUY	$1.33 - $5.93 $1,263 - $5,633	950 Added 102.15%	1,880 $4,000
Q3 2019 Oct 17, 2019	BUY	$5.12 - $7.21 $2,560 - $3,605	500 Added 116.28%	930 $5,000
Q3 2018 Oct 16, 2018	BUY	$10.88 - $14.52 $4,678 - $6,243	430 New	430 $5,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Nisa Investment Advisors, LLC with notifications on news.